Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Evonik says recovery unlikely in 2024, plans 2,000 job cuts

by Staff GBAF Publications Ltd
0 comment

Evonik says recovery unlikely in 2024, plans 2,000 job cuts

(Reuters) – German chemicals group Evonik Industries said on Monday it expected no signs of a recovery in 2024 and announced up to 2,000 job cuts worldwide by 2026 in a bid to cut costs.

The job cuts are expected to lead to reduction costs of 400 million euros annually after completion of the programme, the company said, adding that the majority of the cuts – some 1,500 – would be in Germany.

Evonik, whose products are used in items from animal feed and diapers to Pfizer/BioNTech’s COVID-19 vaccine, expects 2024 adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) in the range of 1.7 billion to 2.0 billion euros ($1.84 billion – $2.17 billion).

This compares with the 1.66 billion euros it reported for 2023, which slightly missed analysts’ forecast of 1.7 billion euros in a company-provided poll.

“What we are currently experiencing are not cyclical fluctuations, but massive, consequential changes of our economic environment,” said CEO Christian Kullmann in a statement.

Chemical companies have been under pressure for more than one year as they were forced to reduce inventories on lower demand from their industrial clients.

The group will propose an annual dividend of 1.17 euros per share, unchanged from the last year.

($1 = 0.9221 euros)


(Reporting by Anastasiia Kozlova and Matteo Allievi in Gdansk; editing by Rachel More)